TY - JOUR
T1 - Effect of halothane on in vivo and in vitro cardiotoxicity of an aminocardenolide
AU - Heerdt, Paul M.
AU - Gallagher, John D.
AU - Caldwell, Robert W.
PY - 1994/6
Y1 - 1994/6
N2 - Halothane opposes cardiotoxicity of neutralβsugar digitalis compounds in intact animals, presumably by depressing a sympathetic component of arrhythmo-genesis. However, halothane also produces a dose-related reduction in arrhythmogenicity of ouabain in isolated canine Purkinje fibers, suggesting that the anesthetic may oppose direct mechanisms of cardiotoxicity as well. The present study examined in vivo and in vitro the effect of halothane on the arrhythmogenicity of ASI-222 (3-β-O[4-amino-4-6-dideoxy-β-D-galactopyranosyl] digi-toxigen in HCl), a highly polar aminocardenolide with no sympathetic component to cardiotoxicity. For in vivo studies, ASI-222 was infused at a rate of 1 μg/kg/min until appearance of third-degree atrioventricular (AV) block or sustained ventricular arrhythmias in 5 conscious (control) and 6 halothane-anesthetized (1.4% end-tidal) dogs. For in vitro studies, standard microelectrode techniques were used to measure action potentials (AP) in seven excised canine Purkinje fibers superfused with oxygenated Krebs-Henseleit buffer. AP were recorded during control superfusion, after induction of toxicity with 10-7M ASI-222, and during exposure to 0.5, 1.0, and 2.0% halothane. Purkinje fibers were paced at 500-ms cycle lengths (CL) for 20 beats, and the amplitude of delayed afterdepolar-izations (DAD) were recorded. Pacing at 250 ms CL was used to trigger ectopy. In vivo studies showed no difference in the cardiotoxic dose of ASI-222 between control dogs and those anesthetized with 1.4% halothane. However, in 4 of 6 anesthetized dogs, acutely increasing the inspired halothane concentration suppressed arrhythmias once end-tidal concentration were > 2.2%. ASI-222 appliβcation to isolated Purkinje fibers induced two DADs (DADI, DAD2) after pacing at 500-ms CL; 2.0% halo thane significantly reduced DADI amplitude, whereas both 1.0 and 2.0% halothane reduced DAD2 amplitude. Pacing at 250-ms CL triggered no extra beats during control superfusion, but did after ASI-222 superfusion. Halothane reduced triggered ectopy in a dose-related fashion, with total elimination at 2.0%. We conclude that halothane opposes the direct cardiotoxicity of ASI-222 when administered at sufficient concentration. However, unlike the dose-related halothane suppression of DAD amplitude and triggered ectopy evident in isolated Purkinje fibers, an end-tidal halothane concentration >2.2% is required in intact dogs to suppress sustained ventricular ectopy. Our data thus suggest that at the low to moderate end-tidal concentrations frequently used clinically halothane opposes cardiotoxicity of conventional digitalis compounds primarily by blunting the sympathetic component of airhythmogenesis.
AB - Halothane opposes cardiotoxicity of neutralβsugar digitalis compounds in intact animals, presumably by depressing a sympathetic component of arrhythmo-genesis. However, halothane also produces a dose-related reduction in arrhythmogenicity of ouabain in isolated canine Purkinje fibers, suggesting that the anesthetic may oppose direct mechanisms of cardiotoxicity as well. The present study examined in vivo and in vitro the effect of halothane on the arrhythmogenicity of ASI-222 (3-β-O[4-amino-4-6-dideoxy-β-D-galactopyranosyl] digi-toxigen in HCl), a highly polar aminocardenolide with no sympathetic component to cardiotoxicity. For in vivo studies, ASI-222 was infused at a rate of 1 μg/kg/min until appearance of third-degree atrioventricular (AV) block or sustained ventricular arrhythmias in 5 conscious (control) and 6 halothane-anesthetized (1.4% end-tidal) dogs. For in vitro studies, standard microelectrode techniques were used to measure action potentials (AP) in seven excised canine Purkinje fibers superfused with oxygenated Krebs-Henseleit buffer. AP were recorded during control superfusion, after induction of toxicity with 10-7M ASI-222, and during exposure to 0.5, 1.0, and 2.0% halothane. Purkinje fibers were paced at 500-ms cycle lengths (CL) for 20 beats, and the amplitude of delayed afterdepolar-izations (DAD) were recorded. Pacing at 250 ms CL was used to trigger ectopy. In vivo studies showed no difference in the cardiotoxic dose of ASI-222 between control dogs and those anesthetized with 1.4% halothane. However, in 4 of 6 anesthetized dogs, acutely increasing the inspired halothane concentration suppressed arrhythmias once end-tidal concentration were > 2.2%. ASI-222 appliβcation to isolated Purkinje fibers induced two DADs (DADI, DAD2) after pacing at 500-ms CL; 2.0% halo thane significantly reduced DADI amplitude, whereas both 1.0 and 2.0% halothane reduced DAD2 amplitude. Pacing at 250-ms CL triggered no extra beats during control superfusion, but did after ASI-222 superfusion. Halothane reduced triggered ectopy in a dose-related fashion, with total elimination at 2.0%. We conclude that halothane opposes the direct cardiotoxicity of ASI-222 when administered at sufficient concentration. However, unlike the dose-related halothane suppression of DAD amplitude and triggered ectopy evident in isolated Purkinje fibers, an end-tidal halothane concentration >2.2% is required in intact dogs to suppress sustained ventricular ectopy. Our data thus suggest that at the low to moderate end-tidal concentrations frequently used clinically halothane opposes cardiotoxicity of conventional digitalis compounds primarily by blunting the sympathetic component of airhythmogenesis.
KW - Aminocardenolide
KW - Cardiotoxicity
KW - Halothane
KW - Purkinje fiber
UR - http://www.scopus.com/inward/record.url?scp=0028360623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028360623&partnerID=8YFLogxK
U2 - 10.1097/00005344-199406000-00006
DO - 10.1097/00005344-199406000-00006
M3 - Article
C2 - 7523780
AN - SCOPUS:0028360623
SN - 0160-2446
VL - 23
SP - 890
EP - 896
JO - Journal of Cardiovascular Pharmacology
JF - Journal of Cardiovascular Pharmacology
IS - 6
ER -